A practical reference on immunomodulatory peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Horseradish peroxidase catalyzes the formation of phenolic radicals in the presence of hydrogen peroxide. Tyrosinase oxidizes phenolic groups into reactive quinones capable of forming crosslinks. Transglutaminase creates covalent bonds between glutamine and lysine residues in polymer chains. These mechanisms enable precise control over crosslinking density, which in turn governs key material properties such as stiffness, degradation rate, and pore size. 1,4 – Butanediol diglycidyl ether (BDDE) Cross-Linked Hyaluronic Acid Fillers
Of the 70,200 overdose deaths in the US in 2017, opioids were involved in 47,600, with three male deaths for each female death. This is an increase from 2016 where over 64,000 died from drug overdose, and opioids were involved in over 42,000. In 2017, the five states with the highest rates of death due to drug overdose were West Virginia (57.8 per 100,000), Ohio (46.3 per 100,000), Pennsylvania (44.3 per 100,000), Kentucky (37.2 per 100,000), and New Hampshire (37.0 per 100,000). Concerning the 2017 data in the charts below, deaths from the various drugs add up to more than 70,200 because multiple substances are involved in many of the deaths. According to the National Safety Council, the lifetime odds of dying from an overdose in the United States is 1 in 96. In 2023, the most opioid overdose deaths were among Whites (47,754), followed by Blacks (16,481), Latinos (11,310), Native Americans (1,170), and Asians (695).
Cooling preserves food by slowing down the growth and reproduction of microorganisms and the action of enzymes that causes the food to rot. The introduction of commercial and domestic refrigerators drastically improved the diets of many in the Western world by allowing food such as fresh fruit, salads and dairy products to be stored safely for longer periods, particularly during warm weather. Before the era of mechanical refrigeration, cooling for food storage occurred in the forms of root cellars and iceboxes. Rural people often did their own ice cutting, whereas town and city dwellers often relied on the ice trade. Today, root cellaring remains popular among people who value various goals, including local food, heirloom crops, traditional home cooking techniques, family farming, frugality, self-sufficiency, organic farming, and others.
Flay served as a judge on Wickedly Perfect, The Next Food Network Star, and The Next Iron Chef. He has cooked on Emeril Live and Paula's Party. On Throwdown! with Bobby Flay, Flay challenges cooks known for a specific dish or type of cooking to a cook-off of their signature dish. Flay was an Iron Chef on the show Iron Chef America. In 2000, when the original Iron Chef show traveled to New York for a special battle, he challenged Iron Chef Masaharu Morimoto to battle rock crab. After the hour battle ended, Flay stood on top of his cutting board and raised his arms in what one journalist wrote was "premature victory". As Morimoto felt that real chefs consider cutting boards and knives sacred, and being offended by Flay's flamboyant gesture, he criticized his professionalism, saying that Flay was "not a chef". Flay went on to lose the battle. Flay challenged Morimoto to a rematch in Morimoto's native Japan. This time, Flay won. On a special episode of Iron Chef America originally airing on November 12, 2006, Flay and Giada De Laurentiis faced off against, and were defeated by, Batali and Rachael Ray. This was the highest rated show ever broadcast on Food Network. Flay and Michael Symon defeated the team of Iron Chefs Cat Cora and Masaharu Morimoto in a special episode titled "Thanksgiving Showdown", which originally aired on November 16, 2008. In an episode recorded in July 2010 and broadcast in March 2011, Montreal cooking show host Chuck Hughes beat Flay to become the youngest Canadian champ.
==== Insulin pump ==== An insulin pump delivers insulin subcutaneously. The insulin pump body itself can also contain the algorithm used in an AID system, or it can connect via Bluetooth with a separate mobile device (such as a phone) to send data and receive commands to adjust insulin delivery. Algorithm The algorithm for each AID system differs. In commercial systems (see below), little is known about the details of how the control algorithm works. In open source systems, the code and algorithm are openly available. In general, all algorithms do the same basic functionality of taking in CGM data and based on predicted glucose level's and the user's personal settings (for basal rates, insulin sensitivity, and carbohydrate ratio, for example) then recommends insulin dosing to help bring or maintain glucose levels in target range. Depending on the system, users may have the ability to adjust the target for the system, and may have different settings to ask the system to give more or less insulin in general.
Sources: en.wikipedia.org
Many metals such as the alkali metals react directly with the electronegative halogens gases to form salts. Solid salts can form upon evaporation of solvent from their solutions once the solution is supersaturated and the solid compound nucleates. This process occurs widely in nature and is the means of formation of the evaporite minerals. Insoluble salts can be precipitated by mixing two solutions, one containing the cation and one containing the anion. Because all solutions are electrically neutral, the two solutions mixed must also contain counterions of the opposite charges. To ensure that these do not contaminate the precipitated salt, it is important to ensure they do not also precipitate. If the two solutions have hydrogen ions and hydroxide ions as the counterions, they will react with one another in what is called an acid–base reaction or a neutralization reaction to form water. Alternately the counterions can be chosen to ensure that even when combined into a single solution they will remain soluble as spectator ions. If the solvent is water in either the evaporation or precipitation method of formation, in many cases the ionic crystal formed also includes water of crystallization, so the product is known as a hydrate, and can have very different chemical properties compared to the anhydrous material. Molten salts will solidify on cooling to below their freezing point. This is sometimes used for the solid-state synthesis of complex salts from solid reactants, which are first melted together.
After Zimbabwe's independence, the new government closed its missions in Pretoria and Cape Town, only maintaining a trade mission in Johannesburg, while the South African Diplomatic Mission in Salisbury was also closed.
Drugs that dilate canaliculi work by inhibiting MLCK or RhoA/Rho-kinase and include diclofenac, bosentan, entacapone, tacrolimus, cimetidine, and flucloxacillin. Constriction is more serious than dilation, as the former causes irreversible cell damage and death. Minor mechanisms that may contribute to DIC include aberrant paracellular permeability, membrane fluidity, and transporter localization. Tight junctions normally seal the gap between hepatocytes to prevent bile from diffusing out of the canaliculi. If a drug causes internalization of hepatocyte tight junctions, like rifampicin does in mice, bile flow may become impaired due to paracellular leakage. Membrane fluidity can affect bile flow by regulating the activity of hepatocyte Na+/K+-ATPase, which maintains the inwardly-directed Na+ gradient that drives BA uptake by apical NTCP. In rats, cyclosporine A was found to increase canalicular membrane fluidity and consequently reduce bile secretion. Bile flow was similarly reduced in rats as a result of alterations to basolateral membrane fluidity by ethinylestradiol and chlorpromazine. Lastly, some agents (rimpaficin and 17β-estradiol) were shown to hinder proper localization of hepatocyte transporters by interfering with the microtubules required for their insertion into plasma membranes.
== External links == ABCC1+protein,+ human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ABCC1 genome location and ABCC1 gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
In May 2002, after then-President Fernando Henrique Cardoso attended a pro-gay-marriage gathering, Bolsonaro said, "If I see two men kissing in the street, I will beat them." He later publicly defended beating gay children, saying, "If your child starts to become like that, a little bit gay, you take a whip and you change their behaviour." He also said, "If a kid hangs out with someone who uses marijuana, he'll end up snorting, and if he hangs out with gay person, he definitely is going to turn into a faggot." In a June 2011 interview with Playboy, Bolsonaro said, "I would be incapable of loving a gay son", and added that he would prefer any gay son of his "to die in an accident". In an interview that same month with Jornal de Notícias, Bolsonaro linked homosexuality to paedophilia, saying, "many of the children who are adopted by gay couples will be abused by these couples". He further argued that Brazil does not need legislation specifically targeting homophobia, because "most homosexuals are murdered by their respective pimps at hours when good citizens are already asleep". In the British actor Stephen Fry's 2013 documentary Out There, Bolsonaro said, "no father is ever proud of having a gay son" and "we Brazilians do not like homosexuals".
==== Surface Modifications ==== Certain properties of polystyrene nanoparticles can be modified depending on the scenario. For instance, the surface of polystyrene nanoparticles can be manipulated by surface oxidation, which creates a surface that is highly receptive with cell cultures. These surface-level modifications also express a lower polydispersity index and can create stable colloids in biological liquid. Similarly, the surface of these nanoparticles can be treated with ethylene oxide or UV irradiation for sterilization purposes. Due to the emphasis on biocompatibility, Loos et al. have utilized polystyrene nanoparticles as a model to analyze how different surface properties affect biomedical variables. Overall, it was determined that a strong understanding of surface properties is vital to manipulate parameters such as pharmacokinetics, biocompatibility, and tissue and cell affinity. In a study conducted by Lundqvist et al., the protein corona was studied with three surface modified polystyrene (plain, carboxyl-modified, and amine-modified) nanoparticles of two different sizes (50 nm and 100 nm). This study ultimately showed that surface corona properties are also affected by size and surface composition.
The concentration of naturally produced HMB has been measured in several human body fluids using nuclear magnetic resonance spectroscopy, liquid chromatography–mass spectrometry, and gas chromatography–mass spectrometry methods. In the blood plasma and cerebrospinal fluid (CSF) of healthy adults, the average molar concentration of HMB has been measured at 4.0 micromolar (μM). The average concentration of HMB in the intramuscular fluid of healthy men of ages 21–23 has been measured at 7.0 μM. In the urine of healthy individuals of any age, the excreted urinary concentration of HMB has been measured in a range of 0–68 micromoles per millimole (μmol/mmol) of creatinine. In the breast milk of healthy lactating women, HMB and L-leucine have been measured in ranges of 42–164 μg/L and 2.1–88.5 mg/L. In comparison, HMB has been detected and measured in the milk of healthy cows at a concentration of <20–29 μg/L. This concentration is far too low to be an adequate dietary source of HMB for obtaining pharmacologically active concentrations of the compound in blood plasma. In a study where participants consumed 2.42 grams of pure HMB-FA while fasting, the average plasma HMB concentration increased from a basal level of 5.1 μM to 408 μM after 30 minutes. At 150 minutes post-ingestion, the average plasma HMB concentration among participants was 275 μM. Abnormal HMB concentrations in urine and blood plasma have been noted in several disease states where it may serve as a diagnostic biomarker, particularly in the case of metabolic disorders.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.